<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608996</url>
  </required_header>
  <id_info>
    <org_study_id>2015-000577-13</org_study_id>
    <nct_id>NCT02608996</nct_id>
  </id_info>
  <brief_title>Nesiritide in Hypertension</brief_title>
  <acronym>TENSE1</acronym>
  <official_title>Therapeutic Effects of BNP in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension remains a global burden in cardiovascular disease leading to stroke, myocardial&#xD;
      infarction, and heart failure. Its myocardial complications result from increased mechanical&#xD;
      load on the heart. Under physiological conditions of increased myocardial load and resulting&#xD;
      myocardial stretch, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP)&#xD;
      synthesis and secretion occur contributing to maintenance of optimal cardiorenal and blood&#xD;
      pressure homeostasis. However, studies indicate that in subjects with cardiovascular diseases&#xD;
      the biological structure of these hormones may be altered, thus reducing their favorable&#xD;
      protective activities. New studies indicate that early and moderate hypertension is&#xD;
      associated with a derangement of the natriuretic peptide system which is characterized by the&#xD;
      lack of activation of biologically active ANP and BNP, while severe hypertension is&#xD;
      characterized by cardiac release of altered molecular forms of ANP and BNP that have reduced&#xD;
      biological properties and/or enhanced degradation.&#xD;
&#xD;
      The broad objective of this proposal is to advance the biology and therapeutics of the NPs&#xD;
      with a special focus on the cardiac peptide BNP in human hypertension. Our proposal is based&#xD;
      upon the biological properties of BNP (i.e. natriuretic, renin-angiotensin-aldosterone&#xD;
      suppressing, vasodilating, anti-fibrotic, anti-hypertrophic and positive lusitropic), its&#xD;
      mechanistic role in human hypertension, and thus its potential as an innovative chronic&#xD;
      protein therapeutic to enhance the treatment of patients with hypertension. Importantly, BNP&#xD;
      is an endocrine hormone normally produced by the human heart, and it has been approved for&#xD;
      the treatment of acute heart failure in USA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in blood pressure (BP)</measure>
    <time_frame>48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection(baseline data) up to 12 hours post last injection.</time_frame>
    <description>Office blood pressure and ambulatory blood pressure monitoring (ABPM) recordings will be used for the analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function as assessed by estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection (baseline data) up to 12 hours post last injection.</time_frame>
    <description>Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin C equation will be used to calculate estimated glomerular filtration rate (eGFR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal changes assessed by aldosterone, atrial natriuretic peptide (ANP), N Terminal-ANP, BNP, N Terminal-proBNP, C-type natriuretic peptide and cyclic guanosyl monophosphate.</measure>
    <time_frame>48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection (baseline data) up to 12 hours post last injection.</time_frame>
    <description>Will be measured in plasma, and all but aldosterone in urine Collections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events defined as all untoward and unintended responses to the treatment related to any dose administered.</measure>
    <time_frame>48 hours, from day 1 to day 2. Specifically, it will be assessed after first injection, up to 12 hours post last injection. A second determination will be done within 3 weeks after last injection (21 days assessment).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Subcutaneous BNP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive gradually increasing doses (10-25 µg/kg) of subcutaneously administered nesiritide (BNP) twice daily for two days, to determine the feasibility, safety and blood pressure lowering effect of BNP so as to identify the optimal dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive subcutaneously administered placebo twice daily for two days for determination of the effect of BNP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nesiritide</intervention_name>
    <description>This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension</description>
    <arm_group_label>Subcutaneous BNP</arm_group_label>
    <other_name>Natrecor, BNP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For comparison to elucidate the true effect of nesiritide</description>
    <arm_group_label>Subcutaneous placebo</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Office systolic blood pressure (SBP) ≥ 120 mmHg and treatment with at least one&#xD;
             anti-hypertensive medication. Unchanged medication regimen the last two weeks prior to&#xD;
             inclusion.&#xD;
&#xD;
          -  Average day-time SBP &gt; 115 on a 24-h ambulatory BP measurement at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congestive Heart Failure (any New York Heart Association class)&#xD;
&#xD;
          -  Ejection Fraction ≤ 40 %&#xD;
&#xD;
          -  Known, not appropriately treated, secondary hypertension&#xD;
&#xD;
          -  Myocardial infarction within 3 months of screening&#xD;
&#xD;
          -  Unstable angina within 14 days of screening, or any evidence of myocardial ischemia&#xD;
&#xD;
          -  Pulmonary hypertension&#xD;
&#xD;
          -  Aortic stenosis with maximum jet velocity &gt; 2,5 m/s&#xD;
&#xD;
          -  Other valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy,&#xD;
             constrictive pericarditis or biopsy proven active myocarditis&#xD;
&#xD;
          -  Sustained Ventricular Tachycardia or Ventricular Fibrillation within 14 days of&#xD;
             screening&#xD;
&#xD;
          -  Sustained Atrial Fibrillation&#xD;
&#xD;
          -  Second or third degree atrioventricular block without a permanent cardiac pacemaker&#xD;
&#xD;
          -  Cerebrovascular event within 3 months of screening, or other evidence of significantly&#xD;
             compromised cerebral perfusion&#xD;
&#xD;
          -  Proteinuria defined as albumin:creatinine ratio &gt; 100 (equivalent to an excretion of &gt;&#xD;
             1 g/day)&#xD;
&#xD;
          -  Nephrotic syndrome&#xD;
&#xD;
          -  Body Mass Index &gt; 35&#xD;
&#xD;
          -  Total bilirubin of &gt; 25 µmol/L, aspartate aminotransferase or alanine aminotransferase&#xD;
             1.5 times the upper limit of normal range&#xD;
&#xD;
          -  Renal insufficiency assessed by estimated glomerular filtration rate (GFR) &lt; 30 ml/min&#xD;
&#xD;
          -  Serum sodium of ≤ 135 mmol/L and ≥ 150 mmol/L&#xD;
&#xD;
          -  Serum potassium of ≤ 3.5 mmol/L and ≥ 5.5 mmol/L&#xD;
&#xD;
          -  Women taking hormonal contraceptives containing estrogens&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients on prolonged, i.e. more than 30 days, immunosuppressant therapy&#xD;
&#xD;
          -  Patients with known, active malignancies&#xD;
&#xD;
          -  Patients with orthostatic hypotension&#xD;
&#xD;
          -  Participation in a trial with an investigational product within the previous three&#xD;
             months&#xD;
&#xD;
          -  Any contraindication listed on the Investigator's Brochure of the Investigational&#xD;
             Medicinal Product&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not&#xD;
             participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Cataliotti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital and University of Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro Cataliotti, MD, PhD</last_name>
    <phone>+47 23016807</phone>
    <email>alessandro.cataliotti@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hopital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hassan Z Khiabani, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hassan Z Khiabani, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Ullevål Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Rostrup, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kaja K Bergo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morten Rostrup, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Einar S Norden</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivar Sjaastad, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Strømmen</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>My HS Svensson, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>My HS Svensson, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helge Røsjø, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Alessandro Cataliotti</investigator_full_name>
    <investigator_title>Professor, dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

